Whole-body knockout of Pparα or hepatocyte-specific deletion of Pparα promoted the development of NAFLD, suggesting Pparα is a potential drug target of NAFLD/NASH36–38. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.